Top

Virology Journal

Published in:

Open Access 01-12-2011 | Research

Cellular phenotype impacts human immunodeficiency virus type 1 viral protein R subcellular localization

Authors: Adriano Ferrucci, Michael R Nonnemacher, Brian Wigdahl

Published in: Virology Journal | Issue 1/2011

Abstract

Background

Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) is a virion-associated regulatory protein that functions at several points within the viral life cycle and has been shown to accumulate primarily in the nucleus and at the nuclear envelope. However, most studies have investigated Vpr localization employing cell types irrelevant to HIV-1 pathogenesis. To gain a better understanding of how cellular phenotype might impact HIV-1 Vpr intracellular localization, Vpr localization was examined in several cell lines representing major cellular targets for HIV-1 infection within the peripheral blood, bone marrow, and central nervous system (CNS).

Results

Utilizing a green fluorescent protein-tagged Vpr, we detected Vpr mainly in foci inside the nucleus, at the nuclear envelope, and around the nucleoli, with dispersed accumulation in the cytoplasm of human endothelial kidney 293T cells. No differences were observed in Vpr localization pattern with respect to either the location of the tag (N- or C-terminus) or the presence of other viral proteins. Subsequently, the Vpr localization pattern was explored in two primary HIV-1 target cells within the peripheral blood: the CD4⁺ T lymphocyte (represented by the Jurkat CD4⁺ T-cell line) and the monocyte-macrophage (represented by the U-937 cell line). Vpr was found primarily in speckles within the cytoplasm of the Jurkat T cells, whereas it accumulated predominantly intranuclearly in U-937 monocytic cells. These patterns differ from that observed in a bone marrow progenitor cell line (TF-1), wherein Vpr localized mainly at the nuclear envelope with some intranuclear punctuate staining. Within the CNS, we examined two astroglioma cell lines and found that Vpr displayed a perinuclear and cytoplasmic distribution.

Conclusions

The results suggest that the pattern of Vpr localization depends on cellular phenotype, probably owing to interactions between Vpr and cell type-specific host factors. These interactions, in turn, are likely coupled to specific roles that Vpr plays in each cell type within the context of the viral life cycle. Phenotype-specific Vpr localization patterns might also provide an explanation with respect to Vpr secretion or release from HIV-1-infected cells within the peripheral blood and CNS.

Available only for authorised users

Cohen EA, Dehni G, Sodroski JG, Haseltine WA: Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 1990, 64: 3097-3099.PubMedCentralPubMed

Paxton W, Connor RI, Landau NR: Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 1993, 67: 7229-7237.PubMedCentralPubMed

Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA: Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol 1999, 73: 4101-4109.PubMedCentralPubMed

Popov S, Rexach M, Zybarth G, Reiling N, Lee MA, Ratner L, Lane CM, Moore MS, Blobel G, Bukrinsky M: Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J 1998, 17: 909-917. 10.1093/emboj/17.4.909PubMedCentralCrossRefPubMed

Sherman MP, de Noronha CM, Eckstein LA, Hataye J, Mundt P, Williams SA, Neidleman JA, Goldsmith MA, Greene WC: Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. J Virol 2003, 77: 7582-7589. 10.1128/JVI.77.13.7582-7589.2003PubMedCentralCrossRefPubMed

Hogan TH, Nonnemacher MR, Krebs FC, Henderson A, Wigdahl B: HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific. Biomed Pharmacother 2003, 57: 41-48. 10.1016/S0753-3322(02)00333-5CrossRefPubMed

Cui J, Tungaturthi PK, Ayyavoo V, Ghafouri M, Ariga H, Khalili K, Srinivasan A, Amini S, Sawaya BE: The role of Vpr in the regulation of HIV-1 gene expression. Cell Cycle 2006, 5: 2626-2638. 10.4161/cc.5.22.3442CrossRefPubMed

Connor RI, Chen BK, Choe S, Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206: 935-944. 10.1006/viro.1995.1016CrossRefPubMed

Subbramanian RA, Kessous-Elbaz A, Lodge R, Forget J, Yao XJ, Bergeron D, Cohen EA: Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med 1998, 187: 1103-1111. 10.1084/jem.187.7.1103PubMedCentralCrossRefPubMed

10.

Nitahara-Kasahara Y, Kamata M, Yamamoto T, Zhang X, Miyamoto Y, Muneta K, Iijima S, Yoneda Y, Tsunetsugu-Yokota Y, Aida Y: Novel nuclear import of Vpr promoted by importin alpha is crucial for human immunodeficiency virus type 1 replication in macrophages. J Virol 2007, 81: 5284-5293. 10.1128/JVI.01928-06PubMedCentralCrossRefPubMed

11.

Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC, Goldsmith MA: HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med 2001, 194: 1407-1419. 10.1084/jem.194.10.1407PubMedCentralCrossRefPubMed

12.

Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin P, Metivier D, Lenoir C, Geuskens M, et al.: Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 2001, 193: 509-519. 10.1084/jem.193.4.509PubMedCentralCrossRefPubMed

13.

Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, Costantini P, Druillennec S, Hoebeke J, Briand JP, et al.: The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000, 191: 33-46. 10.1084/jem.191.1.33PubMedCentralCrossRefPubMed

14.

Stewart SA, Poon B, Jowett JB, Chen IS: Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 1997, 71: 5579-5592.PubMedCentralPubMed

15.

Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR: Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 1995, 69: 7909-7916.PubMedCentralPubMed

16.

Jacquot G, Le Rouzic E, David A, Mazzolini J, Bouchet J, Bouaziz S, Niedergang F, Pancino G, Benichou S: Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology 2007, 4: 84. 10.1186/1742-4690-4-84PubMedCentralCrossRefPubMed

17.

Jenkins Y, McEntee M, Weis K, Greene WC: Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways. J Cell Biol 1998, 143: 875-885. 10.1083/jcb.143.4.875PubMedCentralCrossRefPubMed

18.

Kamata M, Aida Y: Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms. J Virol 2000, 74: 7179-7186. 10.1128/JVI.74.15.7179-7186.2000PubMedCentralCrossRefPubMed

19.

Nakazawa J, Watanabe N, Imoto M, Osada H: Mutational analysis of growth arrest and cellular localization of human immunodeficiency virus type 1 Vpr in the budding yeast, Saccharomyces cerevisiae. J Gen Appl Microbiol 2005, 51: 245-256. 10.2323/jgam.51.245CrossRefPubMed

20.

Sherman MP, de Noronha CM, Heusch MI, Greene S, Greene WC: Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J Virol 2001, 75: 1522-1532. 10.1128/JVI.75.3.1522-1532.2001PubMedCentralCrossRefPubMed

21.

Vodicka MA, Koepp DM, Silver PA, Emerman M: HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998, 12: 175-185. 10.1101/gad.12.2.175PubMedCentralCrossRefPubMed

22.

Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB: Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol 1997, 71: 6339-6347.PubMedCentralPubMed

23.

Morellet N, Roques BP, Bouaziz S: Structure-function relationship of Vpr: biological implications. Curr HIV Res 2009, 7: 184-210. 10.2174/157016209787581490CrossRefPubMed

24.

Pandey RC, Datta D, Mukerjee R, Srinivasan A, Mahalingam S, Sawaya BE: HIV-1 Vpr: a closer look at the multifunctional protein from the structural perspective. Curr HIV Res 2009, 7: 114-128. 10.2174/157016209787581508CrossRefPubMed

25.

Caly L, Saksena NK, Piller SC, Jans DA: Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor. Retrovirology 2008, 5: 67. 10.1186/1742-4690-5-67PubMedCentralCrossRefPubMed

26.

Depienne C, Roques P, Creminon C, Fritsch L, Casseron R, Dormont D, Dargemont C, Benichou S: Cellular distribution and karyophilic properties of matrix, integrase, and Vpr proteins from the human and simian immunodeficiency viruses. Exp Cell Res 2000, 260: 387-395. 10.1006/excr.2000.5016CrossRefPubMed

27.

Waldhuber MG, Bateson M, Tan J, Greenway AL, McPhee DA: Studies with GFP-Vpr fusion proteins: induction of apoptosis but ablation of cell-cycle arrest despite nuclear membrane or nuclear localization. Virology 2003, 313: 91-104. 10.1016/S0042-6822(03)00258-7CrossRefPubMed

28.

Jacquot G, Le Rouzic E, Maidou-Peindara P, Maizy M, Lefrere JJ, Daneluzzi V, Monteiro-Filho CM, Hong D, Planelles V, Morand-Joubert L, Benichou S: Characterization of the molecular determinants of primary HIV-1 Vpr proteins: impact of the Q65R and R77Q substitutions on Vpr functions. PLoS One 2009, 4: e7514. 10.1371/journal.pone.0007514PubMedCentralCrossRefPubMed

29.

Le Rouzic E, Mousnier A, Rustum C, Stutz F, Hallberg E, Dargemont C, Benichou S: Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J Biol Chem 2002, 277: 45091-45098. 10.1074/jbc.M207439200CrossRefPubMed

30.

Wang L, Mukherjee S, Narayan O, Zhao LJ: Characterization of a leucine-zipper-like domain in Vpr protein of human immunodeficiency virus type 1. Gene 1996, 178: 7-13. 10.1016/0378-1119(96)00312-5CrossRefPubMed

31.

Gendelman HE, Baca LM, Husayni H, Turpin JA, Skillman D, Kalter DC, Orenstein JM, Hoover DL, Meltzer MS: Macrophage-HIV interaction: viral isolation and target cell tropism. AIDS 1990, 4: 221-228. 10.1097/00002030-199003000-00007CrossRefPubMed

32.

Lyerly HK, Matthews TJ, Langlois AJ, Bolognesi DP, Weinhold KJ: Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci USA 1987, 84: 4601-4605. 10.1073/pnas.84.13.4601PubMedCentralCrossRefPubMed

33.

He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, et al.: CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997, 385: 645-649. 10.1038/385645a0CrossRefPubMed

34.

Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW: Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 2000,6(Suppl 1):S82-85.PubMed

35.

Wheeler ED, Achim CL, Ayyavoo V: Immunodetection of human immunodeficiency virus type 1 (HIV-1) Vpr in brain tissue of HIV-1 encephalitic patients. J Neurovirol 2006, 12: 200-210. 10.1080/13550280600827377CrossRefPubMed

36.

Churchill MJ, Gorry PR, Cowley D, Lal L, Sonza S, Purcell DF, Thompson KA, Gabuzda D, McArthur JC, Pardo CA, Wesselingh SL: Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 2006, 12: 146-152. 10.1080/13550280600748946CrossRefPubMed

37.

Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, Gorry PR: Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009, 66: 253-258. 10.1002/ana.21697CrossRefPubMed

38.

Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD: Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 1996, 39: 705-711. 10.1002/ana.410390606CrossRefPubMed

39.

Kanmogne GD, Grammas P, Kennedy RC: Analysis of human endothelial cells and cortical neurons for susceptibility to HIV-1 infection and co-receptor expression. J Neurovirol 2000, 6: 519-528. 10.3109/13550280009091952CrossRefPubMed

40.

Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ: Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998, 95: 14500-14505. 10.1073/pnas.95.24.14500PubMedCentralCrossRefPubMed

41.

Piller SC, Ewart GD, Premkumar A, Cox GB, Gage PW: Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. Proc Natl Acad Sci USA 1996, 93: 111-115. 10.1073/pnas.93.1.111PubMedCentralCrossRefPubMed

42.

Rom I, Deshmane SL, Mukerjee R, Khalili K, Amini S, Sawaya BE: HIV-1 Vpr deregulates calcium secretion in neural cells. Brain Res 2009, 1275: 81-86.CrossRefPubMed

43.

Matz MV, Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, Markelov ML, Lukyanov SA: Fluorescent proteins from nonbioluminescent Anthozoa species. Nat Biotechnol 1999, 17: 969-973. 10.1038/13657CrossRefPubMed

44.

Snyder A, Alsauskas Z, Gong P, Rosenstiel PE, Klotman ME, Klotman PE, Ross MJ: FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy. J Virol 2009, 83: 11983-11988. 10.1128/JVI.00034-09PubMedCentralCrossRefPubMed

45.

Nakamura T, Suzuki H, Okamoto T, Kotani S, Atsuji Y, Tanaka T, Ito Y: Recombinant Vpr (rVpr) causes augmentation of HIV-1 p24 Ag level in U1 cells through its ability to induce the secretion of TNF. Virus Res 2002, 90: 263-268. 10.1016/S0168-1702(02)00230-7CrossRefPubMed

46.

de Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, Goldman RD, Greene WC: Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 2001, 294: 1105-1108. 10.1126/science.1063957CrossRefPubMed

47.

Shinya E, Owaki A, Shimizu M, Takeuchi J, Kawashima T, Hidaka C, Satomi M, Watari E, Sugita M, Takahashi H: Endogenously expressed HIV-1 nef down-regulates antigen-presenting molecules, not only class I MHC but also CD1a, in immature dendritic cells. Virology 2004, 326: 79-89. 10.1016/j.virol.2004.06.004CrossRefPubMed

48.

Laguette N, Benichou S, Basmaciogullari S: Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity. J Virol 2009, 83: 1093-1104. 10.1128/JVI.01633-08PubMedCentralCrossRefPubMed

49.

Campbell TD, Khan M, Huang MB, Bond VC, Powell MD: HIV-1 Nef protein is secreted into vesicles that can fuse with target cells and virions. Ethn Dis 2008, 18: S2-14-19.PubMedCentralPubMed

50.

Balasubramanyam A, Mersmann H, Jahoor F, Phillips TM, Sekhar RV, Schubert U, Brar B, Iyer D, Smith EO, Takahashi H, et al.: Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice. Am J Physiol Endocrinol Metab 2007, 292: E40-48.CrossRefPubMed

51.

Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nat Rev Immunol 2005, 5: 69-81. 10.1038/nri1527CrossRefPubMed

52.

Kaul M, Garden GA, Lipton SA: Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001, 410: 988-994. 10.1038/35073667CrossRefPubMed

53.

Maingat F, Halloran B, Acharjee S, van Marle G, Church D, Gill MJ, Uwiera RR, Cohen EA, Meddings J, Madsen K, Power C: Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB J 2011,25(7):2211-20. 10.1096/fj.10-175992PubMedCentralCrossRefPubMed

54.

Shrivastav S, Kino T, Cunningham T, Ichijo T, Schubert U, Heinklein P, Chrousos GP, Kopp JB: Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol 2008, 22: 234-247.PubMedCentralCrossRefPubMed

55.

He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995, 69: 6705-6711.PubMedCentralPubMed

56.

Zhao RY, Li G, Bukrinsky MI: Vpr-Host Interactions During HIV-1 Viral Life Cycle. J Neuroimmune Pharmacol 2011,6(2):216-29. 10.1007/s11481-011-9261-zCrossRefPubMed

57.

Nonaka M, Hashimoto Y, Takeshima SN, Aida Y: The human immunodeficiency virus type 1 Vpr protein and its carboxy-terminally truncated form induce apoptosis in tumor cells. Cancer Cell Int 2009, 9: 20. 10.1186/1475-2867-9-20PubMedCentralCrossRefPubMed

58.

Fritz JV, Didier P, Clamme JP, Schaub E, Muriaux D, Cabanne C, Morellet N, Bouaziz S, Darlix JL, Mely Y, de Rocquigny H: Direct Vpr-Vpr interaction in cells monitored by two photon fluorescence correlation spectroscopy and fluorescence lifetime imaging. Retrovirology 2008, 5: 87. 10.1186/1742-4690-5-87PubMedCentralCrossRefPubMed

59.

Thotala D, Schafer EA, Tungaturthi PK, Majumder B, Janket ML, Wagner M, Srinivasan A, Watkins S, Ayyavoo V: Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. Virology 2004, 328: 89-100. 10.1016/j.virol.2004.07.013CrossRefPubMed

60.

Zhou Y, Lu Y, Ratner L: Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest. Virology 1998, 242: 414-424. 10.1006/viro.1998.9028CrossRefPubMed

61.

Bolton DL, Lenardo MJ: Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1-infected CD4+ T cells. J Virol 2007, 81: 8878-8890. 10.1128/JVI.00122-07PubMedCentralCrossRefPubMed

62.

Muthumani K, Hwang DS, Dayes NS, Kim JJ, Weiner DB: The HIV-1 accessory gene vpr can inhibit antigen-specific immune function. DNA Cell Biol 2002, 21: 689-695. 10.1089/104454902760330237CrossRefPubMed

63.

Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, Kopp J, de Noronha CM, Greene WC, Wray V, Schubert U: Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. J Biol Chem 2000, 275: 32016-32026.CrossRefPubMed

64.

Lahti AL, Manninen A, Saksela K: Regulation of T cell activation by HIV-1 accessory proteins: Vpr acts via distinct mechanisms to cooperate with Nef in NFAT-directed gene expression and to promote transactivation by CREB. Virology 2003, 310: 190-196. 10.1016/S0042-6822(03)00164-8CrossRefPubMed

65.

Xiao Y, Chen G, Richard J, Rougeau N, Li H, Seidah NG, Cohen EA: Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. Virology 2008, 372: 384-397. 10.1016/j.virol.2007.10.036PubMedCentralCrossRefPubMed

66.

Hoshino S, Sun B, Konishi M, Shimura M, Segawa T, Hagiwara Y, Koyanagi Y, Iwamoto A, Mimaya J, Terunuma H, et al.: Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers. AIDS Res Hum Retroviruses 2007, 23: 391-397. 10.1089/aid.2006.0124CrossRefPubMed

67.

Levy DN, Refaeli Y, MacGregor RR, Weiner DB: Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994, 91: 10873-10877. 10.1073/pnas.91.23.10873PubMedCentralCrossRefPubMed

68.

Bouhamdan M, Benichou S, Rey F, Navarro JM, Agostini I, Spire B, Camonis J, Slupphaug G, Vigne R, Benarous R, Sire J: Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J Virol 1996, 70: 697-704.PubMedCentralPubMed

69.

Nilsen H, Otterlei M, Haug T, Solum K, Nagelhus TA, Skorpen F, Krokan HE: Nuclear and mitochondrial uracil-DNA glycosylases are generated by alternative splicing and transcription from different positions in the UNG gene. Nucleic Acids Res 1997, 25: 750-755. 10.1093/nar/25.4.750PubMedCentralCrossRefPubMed

70.

Zhao RY, Li G, Bukrinsky MI: Vpr-Host Interactions During HIV-1 Viral Life Cycle. J Neuroimmune Pharmacol 2011, 6: 216-229. 10.1007/s11481-011-9261-zCrossRefPubMed

71.

Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, Jhamandas J, Power C: HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 2007, 27: 3703-3711. 10.1523/JNEUROSCI.5522-06.2007CrossRefPubMed

72.

Kozak M: At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987, 196: 947-950. 10.1016/0022-2836(87)90418-9CrossRefPubMed

73.

Jenkins Y, Sanchez PV, Meyer BE, Malim MH: Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging. J Virol 2001, 75: 8348-8352. 10.1128/JVI.75.17.8348-8352.2001PubMedCentralCrossRefPubMed

74.

Sherman MP, de Noronha CM, Pearce D, Greene WC: Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J Virol 2000, 74: 8159-8165. 10.1128/JVI.74.17.8159-8165.2000PubMedCentralCrossRefPubMed

75.

Lai M, Chen J: The role of Vpr in HIV-1 disease progression is independent of its G2 arrest induction function. Cell Cycle 2006, 5: 2275-2280. 10.4161/cc.5.19.3317CrossRefPubMed

76.

Zhao LJ, Wang L, Mukherjee S, Narayan O: Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. J Biol Chem 1994, 269: 32131-32137.PubMed

77.

Krichevsky A, Graessmann A, Nissim A, Piller SC, Zakai N, Loyter A: Antibody fragments selected by phage display against the nuclear localization signal of the HIV-1 Vpr protein inhibit nuclear import in permeabilized and intact cultured cells. Virology 2003, 305: 77-92. 10.1006/viro.2002.1765CrossRefPubMed

78.

Zhu Y, Gelbard HA, Roshal M, Pursell S, Jamieson BD, Planelles V: Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. J Virol 2001, 75: 3791-3801. 10.1128/JVI.75.8.3791-3801.2001PubMedCentralCrossRefPubMed

79.

Andersen JL, Zimmerman ES, DeHart JL, Murala S, Ardon O, Blackett J, Chen J, Planelles V: ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis. Cell Death Differ 2005, 12: 326-334. 10.1038/sj.cdd.4401565CrossRefPubMed

80.

Yedavalli VS, Shih HM, Chiang YP, Lu CY, Chang LY, Chen MY, Chuang CY, Dayton AI, Jeang KT, Huang LM: Human immunodeficiency virus type 1 Vpr interacts with antiapoptotic mitochondrial protein HAX-1. J Virol 2005, 79: 13735-13746. 10.1128/JVI.79.21.13735-13746.2005PubMedCentralCrossRefPubMed

81.

Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA: Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 1995, 69: 7032-7044.PubMedCentralPubMed

Title: Cellular phenotype impacts human immunodeficiency virus type 1 viral protein R subcellular localization
Authors: Adriano Ferrucci
Michael R Nonnemacher
Brian Wigdahl
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-8-397

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Susceptibility of human primary neuronal cells to Xenotropic Murine Leukemia Virus-related (XMRV) virus infection

Biotechnological approaches to determine the impact of viruses in the energy crop plant Jatropha curcas

Establishment of real-time quantitative reverse transcription polymerase chain reaction assay for transcriptional analysis of duck enteritis virus UL55 gene

Salmonella Typhimurium-specific bacteriophage ΦSH19 and the origins of species specificity in the Vi01-like phage family

Geminivirus mixed infection on pepper plants: Synergistic interaction between PHYVV and PepGMV

Selection of recombinant MVA by rescue of the essential D4R gene

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials